PMID- 21977598
OWN - NLM
STAT- MEDLINE
DCOM- 20111028
LR  - 20131121
IS  - 1003-9279 (Print)
IS  - 1003-9279 (Linking)
VI  - 25
IP  - 3
DP  - 2011 Jun
TI  - [Relationship between HBeAg seroconversion with genotypes and HBV specific CTL in 
      patients with chronic hepatitis B treated with Adefovir dipivoxil].
PG  - 220-3
AB  - OBJECTIVE: To explore relationship between HBeAg seroconversion with HBV 
      genotypes and HBV specific CTL in patients with chronic hepatitis B (CHB) treated 
      with Adefovir dipivoxil. METHODS: Seventy CHB patients had positive HBV DNA (HBV 
      DNA > or = 1 x 10(4) copy/ml), 45 cases had positive HBeAg, of whom 23 cases (51. 
      11%) had genotype B, 22 cases (48.89%) had genotype C. ALT > 2 x upper limit of 
      normal value (ULN), human leukocyte antigen (HLA)-A(n) positive, patients were 
      treated with Adefovir dipivoxil (commercial name is Mingzheng, Zhengda Tianjing 
      Pharmaceutical Company), 10 mg, orally, once a day. After treatment for 12 
      months, observe relationship between HBeAg seroconversion with HBV genotypes and 
      HBV specific CTL. RESULTS: After treatment with Adefovir dipivoxil for 12 months, 
      HBV specific CTL (0.68% +/- 0.11%) was higher than that before treatment (0.33% 
      +/- 0.11%), t = 8.36 P < 0.001, HBV DNA (3.01 +/- 0.2) log10 copy/ml was lower 
      than that before treatment (6.27 +/- 0.70) log10 copy/ml, t = 12.63 P < 0.001, 
      HBV DNA turned negative (< 500 copy/ml) 43 cases (61.43%), in 45 cases with 
      positive HBeAg, HBeAg turned negative in 13 cases (28.89%), 8 cases had HBeAg 
      seroconversion (17.78%), HBV specific CTL (0.86% +/- 0.05%) of patients with 
      HBeAg seroconversion is higher than (0.61% +/- 0.07%) of patients without HBeAg 
      seroconversion (37 cases, 82.22%) t = 7.88, P < 0.001. In 8 cases with HBeAg 
      seroconversion, 7 cases had genotype B (30.43% of genotype B), 1 cases had 
      genotype C (4.55% of genotype C), chi2 = 5.15, P < 0.05. CONCLUSION: Adefovir 
      dipivoxil can enhance HBV specific cellular immunity of CHB patients. After 
      treatment, occurrence of HBeAg seroconversion is related to increase of HBV 
      specific CTL level and may be related to genotypes.
FAU - Zhou, Yu-Lin
AU  - Zhou YL
AD  - Dept. of Infection, Yixing People's Hospital, Yixing 214200, China. 
      zhouyl972@163.com
FAU - Wang, Xue-Cai
AU  - Wang XC
FAU - Wu, Yin-Tao
AU  - Wu YT
FAU - Tan, Yong-Fei
AU  - Tan YF
FAU - Zhao, Yan-Ping
AU  - Zhao YP
FAU - Tang, Jun-Ming
AU  - Tang JM
FAU - Pan, Jian-Qiang
AU  - Pan JQ
FAU - Yang, Zhi-Xian
AU  - Yang ZX
FAU - Gu, Xi-Bing
AU  - Gu XB
LA  - chi
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
JT  - Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang 
      bingduxue zazhi = Chinese journal of experimental and clinical virology
JID - 9602873
RN  - 0 (Antiviral Agents)
RN  - 0 (Hepatitis B e Antigens)
RN  - 0 (Organophosphonates)
RN  - JAC85A2161 (Adenine)
RN  - U6Q8Z01514 (adefovir dipivoxil)
SB  - IM
MH  - Adenine/*analogs & derivatives/therapeutic use
MH  - Adult
MH  - Antiviral Agents/*therapeutic use
MH  - Female
MH  - Hepatitis B e Antigens/blood/*immunology
MH  - Hepatitis B, Chronic/*drug therapy/*immunology
MH  - Humans
MH  - Immunity, Cellular/drug effects
MH  - Male
MH  - Organophosphonates/*therapeutic use
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 2011/10/08 06:00
MHDA- 2011/10/29 06:00
CRDT- 2011/10/08 06:00
PHST- 2011/10/08 06:00 [entrez]
PHST- 2011/10/08 06:00 [pubmed]
PHST- 2011/10/29 06:00 [medline]
PST - ppublish
SO  - Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Jun;25(3):220-3.